Nutriband Adds Financial Experts to Board as AVERSA™ Fentanyl Push Hits Key Milestones
Event summary
- Nutriband added two new directors: Alessandro Puddu (audit/financial reporting) and Viorica Carlig (operations/compliance).
- AVERSA™ Fentanyl development advanced with Kindeva, including patent grants in Macao and the US, and FDA Type C meeting completion.
- EarthVision Bio’s acquisition of Pocono Pharma delayed; Nutriband collecting $30,000 in penalties.
- Company filed FINRA complaint alleging naked short selling.
- 2026 warrant expiration looms: 910,904 warrants at $6.43 strike price ($5.86M potential exercise).
The big picture
Nutriband’s board refresh signals a focus on financial rigor amid critical AVERSA™ Fentanyl development milestones. The opioid abuse-deterrent patch space is highly competitive, and Nutriband’s ability to navigate regulatory hurdles and secure partnerships will determine its market positioning. The delayed Pocono Pharma sale and FINRA complaint add layers of operational and financial complexity.
What we're watching
- Regulatory Strategy
- Whether Nutriband’s FDA Type C meeting feedback accelerates AVERSA™ Fentanyl’s NDA filing timeline.
- Execution Risk
- The pace at which Nutriband resolves EarthVision Bio’s acquisition delays and recovers penalties.
- Financial Health
- How the FINRA complaint and 2026 warrant expirations impact shareholder sentiment.
Related topics